Literature DB >> 15793647

Sacral nerve stimulation for fecal incontinence following surgery for rectal prolapse repair: a multicenter study.

Michael E D Jarrett1, Klaus E Matzel, Michael Stösser, Cor G M I Baeten, Michael A Kamm.   

Abstract

PURPOSE: A proportion of patients have fecal incontinence secondary to a full-thickness rectal prolapse that fails to resolve following prolapse repair. This multicenter, prospective study assessed the use of sacral nerve stimulation for this indication.
METHODS: Patients had to have more than or equal to four days with fecal incontinence per 21-day period more than one year after surgery. They had to have failed conservative treatment and have an intact external anal sphincter.
RESULTS: Four female patients aged 42, 54, 68, and 65 years met the inclusion criteria. Three of the four patients had had more than one operation for recurrent full-thickness rectal prolapse before sacral nerve stimulation, one of whom had undergone a further operation for recurrence following stimulation. One patient had undergone one operation for prolapse repair. The preoperative duration of symptoms was ten, eight, three, and nine years, respectively. Although patients had an intact external anal sphincter, one patient had a fragmented internal anal sphincter. The frequency of fecal incontinent episodes changed from 11, 24.7, 5, and 8 per week at baseline to 0, 1.5, 5.5, and 1 per week at latest follow-up. Ability to defer defecation was also improved in two of three patients who had this documented. Fecal incontinence-specific quality of life assessment showed an improvement in all four domains.
CONCLUSION: Sacral nerve stimulation should be considered for patients with ongoing fecal incontinence following full-thickness rectal prolapse repair if they prove resistant to conservative treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15793647     DOI: 10.1007/s10350-004-0919-y

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

1.  Meta-analysis: sacral nerve stimulation versus conservative therapy in the treatment of faecal incontinence.

Authors:  Emile Tan; Nye-Thane Ngo; Ara Darzi; Michael Shenouda; Paris P Tekkis
Journal:  Int J Colorectal Dis       Date:  2011-01-29       Impact factor: 2.571

Review 2.  Current status: new technologies for the treatment of patients with fecal incontinence.

Authors:  Andreas M Kaiser; Guy R Orangio; Massarat Zutshi; Suraj Alva; Tracy L Hull; Peter W Marcello; David A Margolin; Janice F Rafferty; W Donald Buie; Steven D Wexner
Journal:  Surg Endosc       Date:  2014-03-08       Impact factor: 4.584

3.  Sacral neuromodulation for faecal incontinence: is the outcome compromised in patients with high-grade internal rectal prolapse?

Authors:  Siriluck Prapasrivorakul; Martijn P Gosselink; Martijn Gosselink; Kim J Gorissen; Simona Fourie; Roel Hompes; Oliver M Jones; Chris Cunningham; Ian Lindsey
Journal:  Int J Colorectal Dis       Date:  2014-11-30       Impact factor: 2.571

4.  [Pelvic floor disorders from the surgeon's viewpoint].

Authors:  T H Schiedeck
Journal:  Chirurg       Date:  2013-10       Impact factor: 0.955

Review 5.  [Rectal prolapse. Abdominal or local approach].

Authors:  K E Matzel; S Heuer; W Zhang
Journal:  Chirurg       Date:  2008-05       Impact factor: 0.955

6.  Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group.

Authors:  E Falletto; E Ganio; G Naldini; C Ratto; D F Altomare
Journal:  Tech Coloproctol       Date:  2013-04-06       Impact factor: 3.781

7.  Altemeier operation associated with dynamic graciloplasty: a case report.

Authors:  Massimo Mongardini; Roberto Paolo Iachetta; Alessandra Cola; Eleonora Degli Effetti; Filippo Custureri
Journal:  J Med Case Rep       Date:  2009-12-04

Review 8.  Systematic review of the impact of sacral neuromodulation on clinical symptoms and gastrointestinal physiology.

Authors:  Naseem Mirbagheri; Yogeesan Sivakumaran; Natasha Nassar; Marc A Gladman
Journal:  ANZ J Surg       Date:  2015-08-05       Impact factor: 1.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.